Thyroid dysfunction in Chinese hepatitis C patients: Prevalence and correlation with TPOAb and CXCL10

Table 1 Demographic characteristics of the enrolled population at baseline

	n = 139
Gender (%, male/female)	50.4/49.6
Age (yr)1	46.8 ± 14.0
HCV RNA (log10, IU/mL)2	6.3 (3.0, 7.74)
ALT (IU/L)2	60.0 (10, 527)
AST (IU/L)2	46.0 (16.0, 264)
TBIL (μmol/L)2	16.1 (5.0, 150)
DBIL (μmol/L)2	4.51 (0.48, 108)
ALB (g/L)1	42.57 ± 4.16
Positive antibodies (%, TPOAb/TGAb)	15.8%/8.6%

¹mean ± SD;

²median (minimum, maximum). TBIL: Total bilirubin; DBIL: Direct bilirubin; TP: Total protein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALB: Albumin; TPOAb: Thyroid peroxidase antibody; TGAb: Thyroglobulin antibody.

Table 2 Summary of thyroid dysfunction induced by pegylated interferon-α2a and ribavirin

No.	Gender	Age(yr)	Diagnosis time	FT3	FT4	TSH	Diagnosis	Outcome
				(3.50-6.50 pmol/L)	(11.48-22.70 pmol/L)	(0.35-5.50 μIU/mL)
1	Female	53	12th wk	4.81	11.66	6.62	Sub hypo	Normal
2	Female	61	48th wk	4.67	12.19	19.61	Sub hypo	Normal
3	Female	42	24th wk	6.02	11.56	7.13	Sub hypo	Normal
4	Female	40	24th wk	5.88	11.71	8.95	Sub hypo	Normal
5	Female	46	24th wk	4.13	14.13	6.25	Sub hypo	Normal
6	Female	56	24th wk	5.46	24.55	11.01	Sub hypo	Normal
7	Female	56	48th wk	5.12	12.89	8.45	Sub hypo	Normal
8	Female	44	48th wk	4.00	24.36	6.31	Sub hypo	Normal
9	Female	41	12th wk	6.19	13.48	5.58	Sub hypo	Sub hyper
10	Female	45	12th wk	5.27	19.24	6.15	Sub hypo	Normal
11	Male	39	24th wk	5.36	13.45	23.19	Sub hypo	Normal
12	Male	28	24th wk	5.44	15.27	6.66	Sub hypo	Normal
13	Male	53	24th wk	3.79	14.67	8.71	Sub hypo	Normal
14	Male	50	12th wk	6.20	11.85	37.42	Sub hypo	Normal
15	Male	51	24th wk	5.15	12.47	6.46	Sub hypo	Normal
16	Male	18	24th wk	4.95	13.99	6.16	Sub hypo	Normal
17	Female	43	24th wk	6.34	13.89	0.32	Sub hyper	Sub hyper
18	Female	21	36th wk	4.37	21.24	0.29	Sub hyper	Normal
19	Female	38	36th wk	5.72	12.97	0.24	Sub hyper	Normal
20	Female	28	24th wk	4.19	21.24	0.32	Sub hyper	Normal
21	Female	42	24th wk	4.67	16.47	0.01	Sub hyper	Normal
22	Female	33	24th wk	5.31	11.58	0.12	Sub hyper	Normal
23	Male	70	24th wk	5.77	16.70	0.02	Sub hyper	Normal
24	Female	21	24th wk	5.90	5.97	6.16	Hypo	Therapy
25	Female	66	48th wk	6.03	0.97	6.58	Hypo	Therapy

Sub hypo: Subclinical hypothyroidism; Sub hyper: Subclinical hyperthyroidism; Hypo: Hypothyroidism.

Table 3 Baseline characteristics of the thyroid dysfunction vs non-thyroid dysfunction chronic hepatitis C patients

	TDIFN	NTDIFN	P value
Gender (%, male/female)	28.0/72.0	55.3/45.7	0.014
Age (yr)1	43.40 ± 13.60	47.50 ± 14.0	0.183
HCV RNA (log10, IU/mL)2	6.23 (3.54, 7.52)	6.36 (3.0, 7.74)	0.919
ALT (IU/L)2	81.0 (26, 416)	55.0 (10, 527)	0.162
AST (IU/L)2	67.0 (26, 248)	41.5 (16, 264)	0.018
TBIL(μmol/L)2	17.20 (8.9, 36.4)	16.0 (5.0, 150.0)	0.732
DBIL(μmol/L)2	4.57 (0.69, 13.80)	4.5 (0.48, 108)	0.447
ALB (g/L)1	42.30 ± 4.24	42.62 ± 4.15	0.764
TPOAb positivity	24.2%	12.3%	0.047
TGAb positivity	12.0%	7.9%	0.469
CXCL10 level (pg/mL)1	310.0 ± 163.4	495.20 ± 244.2	0.012

¹mean ± SD;

²median (minimum, maximum). TBIL: Total bilirubin; DBIL: Direct bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALB: Albumin; TPOAb: Thyroid peroxidase antibody; TGAb: Thyroglobulin antibody.

Table 4 Numbers of patients treated with combination therapy positive for thyroid autoantibodies at enrollment and at the end of treatment

	TPOAb (+) only	TGAb (+) only	Both (+)	Both (-)
At baseline	12	7	5	115
At the end of treatment	13	10	8	108

TPOAb: Thyroid peroxidase antibody; TGAb: Thyroglobulin antibody.